^
Association details:
| Biomarker: | CD276 overexpression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | ITC-6102RO (DNA replication inhibitor, B7-H3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors
Published date:
08/18/2023
Excerpt:
PDX models, generated from B7-H3 highly-expressing human lung tissue, were subjected to ITC-6102RO treatment (Fig. 8A, B). In the 11C38 model, tumor growth was suppressed by 95.9% and 100.1% with ITC-6102RO doses of 0.3 mg/kg and 0.6 mg/kg, respectively, on day ten, accompanied by a significantly increased survival rate (Fig. 8A).
DOI:
https://doi.org/10.1186/s12935-023-02991-x
